<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02072811</url>
  </required_header>
  <id_info>
    <org_study_id>PALG-AML2012</org_study_id>
    <nct_id>NCT02072811</nct_id>
  </id_info>
  <brief_title>Role of the Therapy Tailored to Risk Factors in Treating Adult Patients (≤60) With Acute Myeloid Leukemia</brief_title>
  <acronym>PALG-AML2012</acronym>
  <official_title>Evaluation of the Efficacy of Induction-consolidation Treatment Using a Double Induction in Patients With AML &lt;60 Years Old, Depending on the Percentage of Blasts in the 14 Day, Residual Disease and Leukemic Hematopoietic Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>dr hab. n. med. Agnieszka Wierzbowska</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Polish Adult Leukemia Group, Gliwice, Poland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Copernicus Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Polish Adult Leukemia Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In view of the diversity of the biology of acute myeloid leukemia (AML) therapy in individual&#xD;
      patients must be individualized. One of the tools for this is molecular-cytogenetic&#xD;
      stratification. It divides patients into five categories (prognostic groups): Favorable,&#xD;
      Intermediate-1, Intermediate-2, Adverse and Very adverse risk. After remission proceedings&#xD;
      are tailored depending on prognostic determined groups.&#xD;
&#xD;
      Research of PALG group in the application in the second line regimen CLAG and CLAG-M proved&#xD;
      high effectiveness of this treatment with low toxicity. Considering experience of PALG&#xD;
      groups, it seems that the use of the schema CLAG early as the second induction therapy is a&#xD;
      viable treatment option.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with AML with one of 5 prognostic categories based on modified cytogenetic-molecular&#xD;
      stratification (European Leukemia Net Prognostic System - ENL)&#xD;
&#xD;
      Favorable risk&#xD;
&#xD;
      t(8;21)(q22;q22); RUNX1-RUNX1T1 inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 Mutated&#xD;
      NPM1 without FLT3-ITD (NK) Mutated CEBPA (NK)&#xD;
&#xD;
      Intermediate I risk&#xD;
&#xD;
      Mutated NPM1 with FLT3-ITD (NK) Wild-type NPM1 and FLT3-ITD (NK) Wild-type NPM1 without&#xD;
      FLT3-ITD (NK)&#xD;
&#xD;
      Intermediate II risk&#xD;
&#xD;
      t(9;11)(p22;q22); MLLT3-MLL cytogenic abnormalities other than favorable or adverse&#xD;
&#xD;
      Adverse risk&#xD;
&#xD;
      Inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN-EVI1&#xD;
&#xD;
      Very adverse risk monosomal karyotype (MK): -5 or del(5q); -7; abnl(17p); complex karyotype&#xD;
&#xD;
      Goals:&#xD;
&#xD;
        -  Evaluation of the impact of therapy tailored to the risk factors on outcome of AML&#xD;
           patients aged ≤ 60.&#xD;
&#xD;
        -  Evaluation of the possibility to improve the results of induction therapy through the&#xD;
           use of early 2nd induction in patients with persistent leukemic infiltration of the bone&#xD;
           marrow at the 14th day,&#xD;
&#xD;
        -  Evaluation of the impact of the minimal residual disease (MRD) presence assessed by&#xD;
           Immunophenotyping method, on the results of treatment of AML patients aged ≤ 60,&#xD;
&#xD;
        -  Assessing the significance of monitoring the number of leukemic stem cells (LSC) in bone&#xD;
           marrow and peripheral blood and their influence on clinical course and outcome of AML&#xD;
           treatment,&#xD;
&#xD;
        -  Assessment of the LSC determination usefulness in MRD monitoring in patients with AML,&#xD;
&#xD;
        -  Evaluation of the prognostic significance of the expression of CXCR-4 on the surface of&#xD;
           leukemic cells and their impact on the clinical course and outcome of AML - trying to&#xD;
           select a group of patients who potentially would benefit from the use of&#xD;
           chemosensitization with plerixafor,&#xD;
&#xD;
        -  Evaluation of autologous HSCT effectiveness in consolidation therapy in AML patients&#xD;
           from 3 following cytogenetic-molecular risk groups: Favorable, Intermediate I,&#xD;
           Intermediate II,&#xD;
&#xD;
        -  Comparison of the overall survive (OS) and leukemia-free survival after autologous and&#xD;
           allogeneic HSCT in AML patients from Intermediate I and Intermediate II&#xD;
           cytogenetic-molecular risk groups (biological randomization donor vs. donor).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">February 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete remission after induction</measure>
    <time_frame>28 days</time_frame>
    <description>Outcome measure after induction:&#xD;
At +28 day after treatment or after full morphology recovery (if it occurs before the +28 day)&#xD;
Complete remission, according to Cheson's CR criteria:&#xD;
Lack of extramedullary infiltration,&#xD;
Platelet count&gt; 100 G / L,&#xD;
Neutrophil count&gt; 1.0 G / L,&#xD;
Lack of blast cells in the blood,&#xD;
Bone marrow blasts &lt;5% in the cytomorphology.&#xD;
After induction treatment, patients are qualified for one of the pro-remission treatment options, which is associated with cytogenetic-molecular risk groups, according to the modification of the molecular ELN / MDACC.&#xD;
Therapeutic decisions are being made according to cytogenetic-molecular stratification: Favorable, Intermediate-1, Intermediate-2, Adverse and Very adverse risk.</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Induction, DAC</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The first stage of treatment.&#xD;
First DAC induction cycle is common to all patients (regardless of risk group). After completion of induction I occurs early assessment of bone marrow on the +14 day after the start of treatment (+7 day after completion of chemotherapy).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>II early induction, CLAG</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with blasts in the bone marrow in D14&gt; 10% receive early second induction (CLAG) which start form +16 day.&#xD;
Patients with blasts in the bone marrow in D14 ≤ 10% do not receive early second induction and are qualified to assess the response times on +28 day or after full morphology recovery (if it occurs before the +28 day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Consolidation, I HAM cycle</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>I induction cycle starts after complete remission (CR).&#xD;
- After I consolidation, patients from Intermediate I an Intermediate II group (ELN prognostic system):&#xD;
If compatible donor is present - allogeneic HSCT qualification after I or II consolidation. If compatible donor for allogeneic HSCT is not present - attempt to CD34+ mobilization for autologous SCT after II consolidation&#xD;
- After I consolidation, patients from Adverse risk group (ELN prognostic system):&#xD;
If compatible donor is present - immediate qualification for allogeneic HSCT.&#xD;
- Finding a donor should be initiated in all patients, at the latest after the end of I induction. In the first place, it should be checked whether the patient has a donor family, if not - searching start for an unrelated donor. For patients with no compatible donor for allogeneic HSCT - need to start searching for an alternative donor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>II Consolidation HiDAraC</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients from all 5 risk group receive second after first consolidation [Ara-C] Patient from Very adverse risk receive Ara-C + CLA (Cladribine). If it is needed - more intensive consolidation treatment with 2-Cda.&#xD;
Patients form Very adverse risk receive Maintenance treatment:&#xD;
Decitabine 20 mg/m2 60 min infusion iv (Intravenous injection) for 5 days every 6 weeks.&#xD;
Patients from Favorable, - Intermediate I an Intermediate II risk groups: CD34+ mobilization (HSCT qualification).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Consolidation, III HiDAraC cycle</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients from Favorable, Intermediate I an Intermediate II risk groups receive III consolidation or autologous HSCT (depends on results of mobilization).&#xD;
Patients from Adverse risk receive III Consolidation HiDAraC + Cladribina (CLA) If no CR: CLAG-M reinduction therapy and after CR - treatment according to protocol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DAC</intervention_name>
    <description>DNR 60 mg/m2 0,5h infusion iv on 1-3 days&#xD;
2-CdA 5 mg/m2 2h. infusion iv on 1-5 days&#xD;
Ara-C 200 mg/m2 12h infusion iv 2h after end of infusion with 2CdA on 1-7 days</description>
    <arm_group_label>Induction, DAC</arm_group_label>
    <other_name>- Cladribine</other_name>
    <other_name>- Cytosine arabinoside [Ara-C]</other_name>
    <other_name>- Daunorubicin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CLAG</intervention_name>
    <description>G-CSF 30MU sc, on 0-5 days&#xD;
Mitoxantrone 10mg/m2 30 min infusion iv, on 1-3 days&#xD;
Cladribine 5mg/m2 in 2h infusion iv, on 1-5 days&#xD;
Ara-C 2000mg/m2 4h infusion iv, infusion start after 2h of Cladribine infusion end, on 1-5 day</description>
    <arm_group_label>II early induction, CLAG</arm_group_label>
    <other_name>- Granulocyte-colony stimulating factor [G-CSF]</other_name>
    <other_name>- Cladribine</other_name>
    <other_name>- Mitoxantrone</other_name>
    <other_name>- Cytosine arabinoside [Ara C]</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Consolidation, I HAM cycle</intervention_name>
    <description>Ara-C 3g/m2; 3h infusion iv every 12h on 1,2,3 days&#xD;
Mitoxantrone 10mg/m2; 0,5h infusion iv on 3,4,5 days</description>
    <arm_group_label>Consolidation, I HAM cycle</arm_group_label>
    <other_name>- Mitoxantrone</other_name>
    <other_name>- Cytosine arabinoside [Ara-C]</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>II Consolidation HiDAraC</intervention_name>
    <description>• Ara-C 3g/m2 every 12h; 3h infusion iv on 1,3,5 days (+ mobilization of CD34+)</description>
    <arm_group_label>II Consolidation HiDAraC</arm_group_label>
    <other_name>- Cytosine arabinoside [Ara-C]</other_name>
    <other_name>- Cladribine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Consolidation, III HiDAraC cycle</intervention_name>
    <description>Ara-C 3g/m2 every 12h; 3h infusion iv on 1,3,5 days&#xD;
2-CdA 5 mg/m2 2h infusion iv on 1,3,5 days, 2h before Ara-C</description>
    <arm_group_label>Consolidation, III HiDAraC cycle</arm_group_label>
    <other_name>- Cytosine arabinoside [Ara-C]</other_name>
    <other_name>- 2-CdA [Cladribine, 2-Chlorodeoxyadenosine]</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult acute myeloid leukemia&#xD;
&#xD;
          -  Age: ≥18 and ≤ 60&#xD;
&#xD;
          -  Clinical condition of the patient allows to carry out induction therapy: ECOG&#xD;
             performance status: ≤ 2 and the Hematopoietic Cell Transplant-Co-morbidity Index&#xD;
             (HCT-I): ≤3&#xD;
&#xD;
          -  Informed consent to participate in the study (ICF signed)&#xD;
&#xD;
          -  The second early induction start criteria is in addition to the listed above, the&#xD;
             percentage of the blasts on the level &gt;10% on 7th day.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No informed consent for participation in the study, mental illness, which don't allow&#xD;
             to obtain informed consent and conduct the treatment according to the protocol&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  HIV infection&#xD;
&#xD;
          -  Active cancer&#xD;
&#xD;
          -  Active hepatitis virus infection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Agnieszka Wierzbowska, dr hab.n.med.</last_name>
    <phone>+48426895191</phone>
    <email>agawierzbowska@wp.pl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Agnieszka Pluta, dr n.med.</last_name>
    <phone>+48426895191</phone>
    <email>agnieszka.pluta@op.pl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Copernicus Memorial Hospital</name>
      <address>
        <city>Lodz</city>
        <zip>93-510</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Agnieszka Wierzbowska, Dr hab. n. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <study_first_submitted>February 24, 2014</study_first_submitted>
  <study_first_submitted_qc>February 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2014</study_first_posted>
  <last_update_submitted>February 25, 2014</last_update_submitted>
  <last_update_submitted_qc>February 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 27, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Polish Adult Leukemia Group</investigator_affiliation>
    <investigator_full_name>dr hab. n. med. Agnieszka Wierzbowska</investigator_full_name>
    <investigator_title>PhD in Copernicus Memorial Hospital, Hematology Department</investigator_title>
  </responsible_party>
  <keyword>AML</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
    <mesh_term>Mitoxantrone</mesh_term>
    <mesh_term>Cladribine</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

